EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Linkage of NAMPT promoter variants to eNAMPT secretion, plasma eNAMPT levels, and ARDS severity

Heather Lynn, Xiaoguang Sun, Nancy G Casanova, Christian Bime, Vivian Reyes Hernon, Clayton Lanham, Radu C Oita, Nikolas Ramos, Belinda Sun, Dawn K Coletta, Sara M Camp, Jason H Karnes und 2 weitere

Therapeutic Advances in Respiratory Disease · 2023

DOI: 10.1177/17534666231181262 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Respiratory Disease, 2023. Verfasst von Heather Lynn und 13 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine, University of Arizona Health Sciences, Tucson, AZ, USA. Hauptthemen laut MEDLINE: Nicotinamide Phosphoribosyltransferase, Respiratory Distress Syndrome. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NHLBI NIH HHS, NIH/NHLBI and DOD grants.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and objectives: eNAMPT (extracellular nicotinamide phosphoribosyltransferase), a novel DAMP and TLR4 ligand, is a druggable ARDS therapeutic target with NAMPT promoter SNPs associated with ARDS severity. This study assesses the previously unknown influence of NAMPT promoter SNPs on NAMPT transcription, eNAMPT secretion, and ARDS severity. Methods and design: Human lung endothelial cells (ECs) transfected with NAMPT promoter luciferase reporters harboring SNPs G-1535A, A-1001 C, and C-948A, were exposed to LPS or LPS/18% cyclic stretch (CS) and NAMPT promoter activity, NAMPT protein expression, and secretion assessed. NAMPT genotypes and eNAMPT plasma measurements (Days 0/7) were assessed in two ARDS cohorts (DISCOVERY n = 428; ALVEOLI n = 103).

Results

Comparisons of minor allelic frequency (MAF) in both ARDS cohorts with the 1000 Human Genome Project revealed the G-1535A and C-948A SNPs to be significantly associated with ARDS in Blacks compared with controls and trended toward significance in non-Hispanic Whites. LPS-challenged and LPS/18% CS–challenged EC harboring the -1535G wild-type allele exhibited significantly increased NAMPT promoter activity (compared with -1535A) with the -1535G/-948A diplotype exhibiting significantly increased NAMPT promoter activity, NAMPT protein expression, and eNAMPT secretion compared with the -1535A/-948 C diplotype. Highly significant increases in Day 0 eNAMPT plasma values were observed in both DISCOVERY and ALVEOLI ARDS cohorts (compared with healthy controls). Among subjects surviving to Day 7, Day 7 eNAMPT values were significantly increased in Day 28 non-survivors versus survivors. The protective -1535A SNP allele drove -1535A/-1001A and -1535A/-948 C diplotypes that confer significantly reduced ARDS risk (compared with -1535G, -1535G/-1001 C, -1535G/-948A), particularly in Black ARDS subjects. NAMPT SNP comparisons within the two ARDS cohorts did not identify significant association with either APACHE III scores or plasma eNAMPT levels.

Conclusion

NAMPT SNPs influence promoter activity, eNAMPT protein expression/secretion, plasma eNAMPT levels, and ARDS severity. NAMPT genotypes are a potential tool for stratification in eNAMPT-focused ARDS clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nicotinamide PhosphoribosyltransferaseRespiratory Distress SyndromeHumansEndothelial CellsLipopolysaccharidesCytokinesLung

Stichwörter der Autor:innen

acute respiratory distress syndrome (ARDS)enzyme-linked immunosorbent assayextracellular nicotinamide phosphoribosyltransferase (eNAMPT)genotype–phenotypeluciferase reporter

Substanzen

Nicotinamide PhosphoribosyltransferaseLipopolysaccharidesCytokines

Autor:innen und Institutionen

  • College of Medicine, University of Arizona Health Sciences, Tucson, AZ, USA.
  • College of Pharmacy, University of Arizona Health Sciences, Tucson, AZ, USA.
  • Dr. Herbert A. Wertheim Professor of Inflammation Science, Director, Center for Inflammation Science and Systems Medicine, University of Florida Scripps Research Institute, Jupiter, FL 33458, USA.

ORCID-Profile: Joe G N Garcia

Förderung

  • NHLBI NIH HHS
  • NIH/NHLBI and DOD grants

Zitieren

APA

Lynn, H., Sun, X., Casanova, N. G., Bime, C., Reyes Hernon, V., Lanham, C., Oita, R. C., Ramos, N., Sun, B., Coletta, D. K., Camp, S. M., Karnes, J. H., Ellis, N. A., & Garcia, J. G. N. (2023). Linkage of NAMPT promoter variants to eNAMPT secretion, plasma eNAMPT levels, and ARDS severity. Therapeutic Advances in Respiratory Disease. https://doi.org/10.1177/17534666231181262

Vancouver

Lynn H, Sun X, Casanova NG, Bime C, Reyes Hernon V, Lanham C, et al. Linkage of NAMPT promoter variants to eNAMPT secretion, plasma eNAMPT levels, and ARDS severity. Therapeutic Advances in Respiratory Disease. 2023. doi:10.1177/17534666231181262

BibTeX
@article{Lynn2023,
  author = {Lynn, Heather and Sun, Xiaoguang and Casanova, Nancy G and Bime, Christian and Reyes Hernon, Vivian and Lanham, Clayton and Oita, Radu C and Ramos, Nikolas and Sun, Belinda and Coletta, Dawn K and Camp, Sara M and Karnes, Jason H and Ellis, Nathan A and Garcia, Joe G N},
  title = {Linkage of NAMPT promoter variants to eNAMPT secretion, plasma eNAMPT levels, and ARDS severity},
  journal = {Therapeutic Advances in Respiratory Disease},
  year = {2023},
  doi = {10.1177/17534666231181262}
}
Kostenlos starten →